Overview

This book brings together a range of academic, industry and practitioner perspectives on translational medicine (TM) to significantly enhance conceptual and practical understanding of the emergence and progress of the field and its potential impact on basic research, therapeutic development, and institutional infrastructure/resources. In recognition of the various implications TM has for public health policy and commercial innovation, this cutting-edge, interdisciplinary book addresses the major systemic aspects of the field.

Full Product Details

Author:   James Mittra (University of Edinburgh, UK) ,  Christopher-Paul Milne (Tufts University, Boston, Massachusetts, USA)
Publisher:   Pan Stanford Publishing Pte Ltd
Imprint:   Pan Stanford Publishing Pte Ltd
Dimensions:   Width: 15.20cm , Height: 2.30cm , Length: 22.90cm
Weight:   0.612kg
ISBN:  

9789814316996

ISBN 10:   9814316997
Pages:   294
Publication Date:   17 April 2013
Audience:   College/higher education ,  Professional and scholarly ,  Tertiary & Higher Education ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Active
Availability:   Manufactured on demand  
We will order this item for you from a manufactured on demand supplier.

Table of Contents

"Introduction: Introduction to Translational Medicine. Drivers and Barriers to Translational Medicine: New Light Through an Old Window? The ""Translational Turn"" in Biomedical Research — A Historical Perspective. Translational Medicine: The Industry Perspective. Drivers and Barriers of Translational Medicine: A Regulatory Perspective. Developing an Evaluation Model for Translational Medicine Research Programs. State of the Art in Science and Technology: Emerging Concepts in Biomarker Discovery: Cancer Immunotherapy and Degenerative Diseases of the Eye as Model Systems. Imaging Biomarkers for Innovative Drug Development: Translation from Bench to Bedside and Back. Translational Bioinformatics: Bridging the Biological and Clinical Divide. Institutional Dynamics of Translational Medicine: Exploiting Translational Medicine Through Public–Private Partnerships: A Case Study of Scotland’s Translational Medicine Research Collaboration (TMRC). The Role of the Product Development Partnership as a Translational Mechanism for Delivering Health Solutions in Low-Resource Settings. Conclusions: Is Translational Medicine the Future of Therapy?"

Reviews

This is a book that should be read by all those aiming to improve the efficiency and effectiveness of translation of science into clinical practice and health outcomes. Unlike other contributions in the field, it takes a holistic approach to the problem and recognises the dynamic nature of demand for as well as supply of health innovation, identifying strategies to integrate the two. This book has been needed for some time, but, with stagnating productivity and ever-increasing economic pressures, never more so than right now. -Prof. Iain Gillespie, The University of Edinburgh, UK

This is a book that should be read by all those aiming to improve the efficiency and effectiveness of translation of science into clinical practice and health outcomes. Unlike other contributions in the field, it takes a holistic approach to the problem and recognises the dynamic nature of demand for as well as supply of health innovation, identifying strategies to integrate the two. This book has been needed for some time, but, with stagnating productivity and ever-increasing economic pressures, never more so than right now. -Prof. Iain Gillespie, The University of Edinburgh, UK

Author Information

James Mittra is a research fellow and lecturer at the ESRC Innogen Centre and Science, Technology and Innovation Studies subject group at the University of Edinburgh. His research and teaching focuses on interdisciplinary approaches to the complex and dynamic ways in which life sciences are affecting the nature and the process of technological and therapeutic innovation within the pharmaceutical and biotechnology sectors. Dr. Mittra has published widely on issues of the strategic management and governance of the life sciences, as well as on mapping new value systems and business models for novel therapies. Christopher-Paul Milne is director of research at the Tufts Center for the Study of Drug Development. His current research interests include academic–industry collaborations; disease, demographic, and market access factors in the emerging markets; incentive programs for pediatric studies, orphan products, and neglected diseases; and tracking the progress of new regulatory and research initiatives such as regulatory science, comparative effectiveness research, translational medicine, and personalized medicine. Dr. Milne is also research assistant professor at Tufts University Medical School, member of the editorial board of the Food & Drug Law Journal, and an honorary fellow at the University of Edinburgh.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions